利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的有效性及不良反应分析  

Analysis of the effectiveness and adverse reactions of liraglutide combined with insulin aspart 30 in the treatment of refractory type 2 diabetes mellitus

作　　者：宋长虹[1] 刘起群 SONG Chang-hong;LIU Qi-qun(Department of Stomatology,Feixian County People's Hospital,Linyi 273400,China)

机构地区：[1]费县人民医院内分泌科,273400 [2]费县人民医院口腔科,273400

出　　处：《中国实用医药》2025年第3期34-37,共4页China Practical Medicine

摘　　要：目的对难治性2型糖尿病患者使用利拉鲁肽联合门冬胰岛素30进行治疗的效果做出分析。方法80例难治性2型糖尿病患者,采用随机抽样法分为常规组和研究组,各40例。常规组患者使用门冬胰岛素30治疗,研究组患者使用利拉鲁肽联合门冬胰岛素30治疗。对比两组患者治疗效果、不良反应发生率、血糖水平、体质量指数、C肽水平、胰岛功能指标。结果研究组患者治疗总有效率为97.50%,高于常规组的80.00%(P<0.05)。研究组患者不良反应发生率为5.00%,低于常规组的22.50%(P<0.05)。治疗后,研究组患者空腹血糖(6.13±0.34)mmol/L、餐后2 h血糖(8.25±0.25)mmol/L、糖化血红蛋白(5.48±0.58)%、C肽(1.03±0.12)μg/L、体质量指数(24.01±4.87)kg/m^(2)均低于常规组的(7.97±0.82)mmol/L、(8.89±0.89)mmol/L、(7.47±0.82)%、(2.39±0.38)μg/L、(28.25±4.23)kg/m^(2)(P<0.05)。治疗后,研究组患者胰岛素抵抗指数、空腹胰岛素低于常规组,胰岛素分泌指数高于常规组(P<0.05)。结论为难治性2型糖尿病患者使用利拉鲁肽联合门冬胰岛素30治疗,能够优化患者血糖指标,降低患者体质量指数,改善其胰岛功能,治疗效果较高,临床应用价值较高。Objective To analyze the effect of liraglutide combined with insulin aspart 30 in the treatment of refractory type 2 diabetes mellitus.Methods A total of 80 patients with refractory type 2 diabetes mellitus were randomly divided into a conventional group and a study group,with 40 cases in each group.The conventional group was treated with insulin aspart 30,while the study group was treated with liraglutide combined with insulin aspart 30.The therapeutic effect,incidence of adverse reactions,blood glucose level,body mass index,C-peptide level and islet function index were compared between the two groups.Results The total effective rate of the study group was 97.50%,which was higher than 80.00%of the conventional group(P<0.05).The incidence of adverse reactions in the study group was 5.00%,which was lower than 22.50%in the conventional group(P<0.05).After treatment,the fasting blood glucose of the study group was(6.13±0.34)mmol/L,the 2 h postprandial blood glucose was(8.25±0.25)mmol/L,the glycated hemoglobin was(5.48±0.58)%,the C-peptide was(1.03±0.12)μg/L,and the body mass index was(24.01±4.87)kg/m^(2),which were lower than(7.97±0.82)mmol/L,(8.89±0.89)mmol/L,(7.47±0.82)%,(2.39±0.38)μg/L,and(28.25±4.23)kg/m^(2) in the conventional group(P<0.05).After treatment,the insulin resistance index and fasting insulin in the study group were lower than those in the conventional group,and the insulin secretion index was higher than that in the conventional group(P<0.05).Conclusion Liraglutide combined with insulin aspart 30 has high therapeutic effect for patients with refractory type 2 diabetes mellitus,which can optimize blood glucose index,reduce body mass index and improve islet function.It has high clinical application value.

关 键 词：利拉鲁肽 门冬胰岛素30 难治性2型糖尿病 有效性 不良反应 

分 类 号：R587.1[医药卫生—内分泌]